<DOC>
	<DOC>NCT01691261</DOC>
	<brief_summary>Phase 1 trial of retinal pigment epithelium replacement in subjects with wet age-related macular degeneration in whom there is rapidly progressing vision loss</brief_summary>
	<brief_title>A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration</brief_title>
	<detailed_description>Phase 1, open-label, safety and feasibility study of implantation of PF-05206388 (human embryonic stem cell derived retinal pigment epithelium) in subjects with wet age related macular degeneration and rapid vision loss</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Male and /or postmenopausal female subjects aged 60 years or above. Diagnosis of wet Agerelated Macular Degeneration (AMD) plus rapid recent vision decline An informed consent document signed and dated by the subject or a legal representative. Pregnant females; breastfeeding females; and females of childbearing potential. Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication. Current or previous significant other ocular disease in the study eye, as determined by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>